Societal value of stem cell therapy in stroke--a modeling study

Area of Science:

• Neuroscience
• Regenerative Medicine
• Health Economics

Background:

• Stroke is a leading cause of adult disability with limited recovery options.
• Cell transplantation in animal models shows potential for neural repair.
• Stem cell therapy (SCT) may improve functional recovery and reduce societal costs for stroke patients.

Purpose of the Study:

• To estimate the potential societal value of stem cell therapy (SCT) in stroke patients.
• To assess the cost-effectiveness and quality-adjusted life years (QALYs) of SCT compared to standard care.

Main Methods:

• A decision-analytic model was developed to assess life-long costs and QALYs from a societal perspective.
• The model incorporated factors like age, functional status (mRS), SCT effectiveness, administration, and complication risks.
• Societal willingness to pay for QALY gain in Sweden was used to interpret the value of SCT.

Main Results:

• SCT in a 55-year-old patient with mRS 2 at discharge yielded a gain of 1.34 QALYs and 1.06 life years.
• Despite increased intervention costs, SCT led to cost savings of $19,055 USD due to decreased productivity losses.
• The societal value of SCT was estimated at $166,500 USD, assuming a zero price for stem cells.

Conclusions:

• SCT demonstrates significant societal value, particularly for younger stroke patients with moderate disability.
• While initial transplantation costs are higher, SCT can lead to long-term cost offsets and savings by reducing stroke-related disability.
• Further research into SCT for stroke therapy holds potential for substantial societal benefit and cost-effectiveness.